GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.
The invention relates to dasiglucagon, a glucagon analogue, or a pharmaceutically acceptable salt or solvate thereof, for the treatment of congenital hyperinsulinism.
The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
Compounds of formula (I):
Compounds of formula (I):
Compounds of formula (I):
and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical and medical preparations.
(2) Computer hardware and software for use and in connection with pharmaceutical and medical devices and instruments.
(3) Pharmaceutical and medical devices and instruments.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for medical purposes; synthetic
peptides for pharmaceuticals purposes; pharmaceutical
preparations for the treatment of diseases, illnesses and
ailments in humans, such as pharmaceutical preparations for
treating endocrine disorders, immunity disorders,
nutritional and metabolic diseases, such as diabetes and
obesity; pharmaceutical preparations for the treatment and
prevention of hypoglycemia; hypoglycemic agents; medical
preparations in the nature of a liquid solution for medical
purposes for the treatment and prevention of hypoglycemia;
pharmaceutical preparations for treating gastrointestinal
diseases, such as short bowel syndrome and ulcerative
colitis; pharmaceutical preparations altering the immune
system, such as complement inhibitors; apparatus and
instruments containing pharmaceutical preparations,
substances and medicines; medical rescue injection pens
containing glucagon to treat severe cases of low blood
sugar; pre-filled syringes for medical purposes. Computer software, including application software for
smartphones [mobile phones], for tablet computers and other
handheld or portable personal computers and for personal
computers, all for determining treatment recommendations,
dose calculation and patient support programs in the nature
of providing medical information; databases and software,
including application software and databases for use in
connection with medical diagnosing, treatment, treatment
planning and patient support programs; downloadable software
configured for insulin monitoring and tracking blood glucose
levels; downloadable software configured for the collection,
editing, organizing, modifying, book marking, transmission,
storage, sharing and analysis of data and information in the
field of diabetes management; wearable devices for insulin
monitoring; computer hardware and software for use with
medical injection devices for collecting, transmitting and
displaying medical data; medical software for the management
of diabetes, obesity or gastrointestinal diseases;
electronic publications, namely, leaflets, books, booklets,
handouts, magazines as well as medical, instructional and
teaching material in the field of diabetes, obesity and
gastrointestinal diseases. Instruments and apparatus for administering pharmaceuticals;
medical devices, namely, diabetes management devices,
infusion and injection devices, infusion pumps, infusion
pump controllers and parts and attachments thereof; medical
devices and sensors used to continuously monitor the
concentration of glucose in the human body; glucose
monitors; glucose monitor accessories, namely, transmitters,
receivers, and medical sensor insertion devices; wearable
medical devices for insulin monitoring; infusion pumps for
improvement of glycemic control and auto-injector pens for
the treatment of hypoglycemia; medical rescue injection pens
for administrating glucagon; parts and accessories for all
the aforesaid goods. Scientific and technological services and research and
design relating thereto in the field of medicine,
pharmaceuticals, genetics, biology and biotechnology;
industrial analysis and research services in the field of
medicine, pharmaceuticals, genetics, biology and
biotechnology; medical, biological, biotechnological,
genetic, laboratory and pharmaceutical research, design and
development services; laboratory research in the field of
medicine, pharmaceuticals, genetics, biology and
biotechnology; information and consultancy services relating
to all the aforesaid; providing scientific information on
diabetes, obesity and gastrointestinal diseases; hosting of
websites and mobile apps in relation to technology that
enables users to record, track, and generate reports
regarding the condition, treatment and the management of
diabetes, obesity and gastrointestinal diseases; computer
services, namely providing access to data concerning medical
analysis and management of diabetes, obesity and
gastrointestinal diseases; clinical trials. Medical services; medical analysis services for the
diagnosis and treatment of humans; medical consulting
services in the field of diseases, illnesses and ailments in
humans; medical services related to the testing and
treatment of patients with diabetes or low blood sugar
(hypoglycemia); medical services related to testing and
treatment of patients with gastrointestinal diseases, such
as short bowel syndrome and ulcerative colitis; medical
consulting services, namely, providing patient adherence
programs to patients suffering from diabetes, obesity or
gastrointestinal diseases; providing medical information via
a website that provide a patient adherence program to
patients suffering from diabetes, obesity or
gastrointestinal diseases; medical information services,
namely, providing information relating to the treatment of
diabetes, obesity or gastrointestinal diseases; medical
advisory services, namely providing advisory services
relating to the treatment of diabetes, obesity or
gastrointestinal diseases; medical services in the nature of
patient support relating to the treatment of diabetes,
obesity or gastrointestinal diseases; medical information
and advice in relation to treatment planning, including
information and advice provided via the Internet, databases
and application software; consultancy services relating to
the aforesaid.
The present invention relates to use of an amylin analogue and a dual agonist of the gastric inhibitory polypeptide receptor (GIPR) and the glucagon-like peptide- 1 receptor (GLP-1R) to regulate body weight and to treat or prevent obesity and related conditions.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to therapeutic and non-therapeutic methods using peptide hormone analogues. In particular, the invention relates to use of amylin analogues with improved properties, specifically amylin analogues that do not delay gastric emptying.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to therapeutic and non-therapeutic methods using peptide hormone analogues. In particular, the invention relates to amylin analogues for the regulation of body weight, such as the reduction of body weight, and for the prophylaxis or treatment of obesity and related conditions. Specifically, the invention relates to one-off, sporadic, or infrequent dosing of the amylin analogues in said methods.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease such as Crohn's disease or ulcerative colitis, psoriatic arthritis and psoriasis. The compounds have good physical and chemical stability in the gastrointestinal tract.
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease such as Crohn's disease or ulcerative colitis, psoriasis and psoriatic arthritis. The compounds have good physical and chemical stability in the gastrointestinal tract.
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and medical preparations. Computer hardware and software for use and in connection
with pharmaceutical and medical devices and instruments. Pharmaceutical and medical devices and instruments.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely for treatment of human
patients suffering from CHI (Congenital HyperInsulinism)
and/or hypoglycemia; medical preparations for the treatment
of human patients suffering from CHI (Congenital
HyperInsulinism) and/or hypoglycemia. Infusion pumps; medical devices, namely, infusion pumps for
subcutaneous delivery of drugs; medical apparatus, namely,
infusion and injection devices for administering drugs;
medical apparatus, namely, infusion and injection devices
for administering drugs for the treatment of congenital
hyperinsulinism (CHI); medical apparatus, namely, infusion
and injection devices for administering drugs for the
treatment of hypoglycemia; infusion and injection devices
for administering drugs and parts and fittings therefor;
infusion pumps and parts and fittings therefor. Medical services relating to treatment of human patients
suffering from CHI (Congenital HyperInsulinism) and/or
hypoglycemia.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely for treatment of human
patients suffering from CHI (Congenital HyperInsulinism)
and/or hypoglycemia; medical preparations for the treatment
of human patients suffering from CHI (Congenital
HyperInsulinism) and/or hypoglycemia. Infusion pumps; medical devices, namely, infusion pumps for
subcutaneous delivery of drugs; medical apparatus, namely,
infusion and injection devices for administering drugs;
medical apparatus, namely, infusion and injection devices
for administering drugs for the treatment of congenital
hyperinsulinism (CHI); medical apparatus, namely, infusion
and injection devices for administering drugs for the
treatment of hypoglycemia; infusion and injection devices
for administering drugs and parts and fittings therefor;
infusion pumps and parts and fittings therefor. Medical services relating to treatment of human patients
suffering from CHI (Congenital HyperInsulinism) and/or
hypoglycemia.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for medical purposes; synthetic peptides for pharmaceuticals purposes; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, such as pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes. Computer software, including application software for smartphones [mobile phones], for tablet computers and other handheld or portable personal computers and for personal computers, all for determining treatment recommendations, dose calculation and patient support programs in the nature of providing medical information; databases and software, including application software and databases for use in connection with medical diagnosing, treatment, treatment planning and patient support programs; downloadable software configured for insulin monitoring and tracking blood glucose levels; downloadable software configured for the collection, editing, organizing, modifying, book marking, transmission, storage, sharing and analysis of data and information in the field of diabetes management; wearable devices for insulin monitoring; computer hardware and software for use with medical injection devices for collecting, transmitting and displaying medical data; medical software for the management of diabetes, obesity or gastrointestinal diseases; electronic publications, namely, leaflets, books, booklets, handouts, magazines as well as medical, instructional and teaching material in the field of diabetes, obesity and gastrointestinal diseases. Instruments and apparatus for administering pharmaceuticals; medical devices, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; glucose monitors; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods. Scientific and technological services and research and design relating thereto in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; hosting of websites and mobile apps in relation to technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely providing access to data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases; clinical trials. Medical services; medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing medical information via a website that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for medical purposes; synthetic peptides for pharmaceuticals purposes; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, such as pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes.
(2) Computer software, including application software for smartphones [mobile phones], for tablet computers and other handheld or portable personal computers and for personal computers, all for determining treatment recommendations, dose calculation and patient support programs in the nature of providing medical information; databases and software, including application software and databases for use in connection with medical diagnosing, treatment, treatment planning and patient support programs; downloadable software configured for insulin monitoring and tracking blood glucose levels; downloadable software configured for the collection, editing, organizing, modifying, book marking, transmission, storage, sharing and analysis of data and information in the field of diabetes management; wearable devices for insulin monitoring; computer hardware and software for use with medical injection devices for collecting, transmitting and displaying medical data; medical software for the management of diabetes, obesity or gastrointestinal diseases; electronic publications, namely, leaflets, books, booklets, handouts, magazines as well as medical, instructional and teaching material in the field of diabetes, obesity and gastrointestinal diseases.
(3) Instruments and apparatus for administering pharmaceuticals; medical devices, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; glucose monitors; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods. (1) Scientific and technological services and research and design relating thereto in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; hosting of websites and mobile apps in relation to technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely providing access to data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases; clinical trials.
(2) Medical services; medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing medical information via a website that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and medical preparations. Computer hardware and software for use and in connection with pharmaceutical and medical devices and instruments. Pharmaceutical and medical devices and instruments.
The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid formulations of amylin analogues.
The present invention relates to a composition comprising a GLP-1/GLP-2 dual agonist for use in a method for the treatment and/or prevention of diarrhea, loose stools, urgency, incontinence, high fecal output and/or high stomal output in a patient having undergone surgical resection of the bowel.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia. Infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of congenital hyperinsulinism (CHI); medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of hypoglycemia; infusion and injection devices for administering drugs and parts and fittings therefor; infusion pumps and parts and fittings therefor. Medical services relating to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
(2) Infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of congenital hyperinsulinism (CHI); medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of hypoglycemia; infusion and injection devices for administering drugs and parts and fittings therefor; infusion pumps and parts and fittings therefor. (1) Medical services relating to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
(2) Infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of congenital hyperinsulinism (CHI); medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of hypoglycemia; infusion and injection devices for administering drugs and parts and fittings therefor; infusion pumps and parts and fittings therefor. (1) Medical services relating to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely for treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia; medical preparations for the treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia. Infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of congenital hyperinsulinism (CHI); medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of hypoglycemia; infusion and injection devices for administering drugs and parts and fittings therefor; infusion pumps and parts and fittings therefor. Medical services relating to treatment of human patients suffering from CHI (Congenital HyperInsulinism) and/or hypoglycemia.
26.
GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES AND THEIR MEDICAL USES FOR THE TREATMENT OF SHORT BOWEL SYNDROME (SBS)
Glucagon-like-peptide-2 (GLP-2) analogues and their medical uses the treatment of short bowel syndrome (SBS) are disclosed, in particular medical uses of glepaglutide identied in the EASE SBS 1 trial demonstrating improved patient Quality of Life (QoL) and/or an early reduction in the parenteral support (PS) required by patients as their treatment with glepaglutide progressed.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS).
(2) Devices for introducing pharmaceutical preparations, namely for treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS). (1) Medical and pharmaceutical services, namely in relation to treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS); medical and pharmaceutical advice, namely in relation to treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, such as Short Bowel Syndrome (SBS).
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely for treatment and
prevention of stomach and bowel-related disorders and
gastrointestinal diseases and disorders in humans, such as
Short Bowel Syndrome (SBS). Devices for introducing pharmaceutical preparations, namely
for treatment and prevention of stomach and bowel-related
disorders and gastrointestinal diseases and disorders in
humans, such as Short Bowel Syndrome (SBS). Medical and pharmaceutical services, namely in relation to
treatment and prevention of stomach and bowel-related
disorders and gastrointestinal diseases and disorders in
humans, such as Short Bowel Syndrome (SBS); medical and
pharmaceutical advice, namely in relation to treatment and
prevention of stomach and bowel-related disorders and
gastrointestinal diseases and disorders in humans, such as
Short Bowel Syndrome (SBS).
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely for treatment and
prevention of stomach and bowel-related disorders and
gastrointestinal diseases and disorders in humans, such as
Short Bowel Syndrome (SBS). Devices for introducing pharmaceutical preparations, namely
for treatment and prevention of stomach and bowel-related
disorders and gastrointestinal diseases and disorders in
humans, such as Short Bowel Syndrome (SBS). Medical and pharmaceutical services, namely in relation to
treatment and prevention of stomach and bowel-related
disorders and gastrointestinal diseases and disorders in
humans, such as Short Bowel Syndrome (SBS); medical and
pharmaceutical advice, namely in relation to treatment and
prevention of stomach and bowel-related disorders and
gastrointestinal diseases and disorders in humans, such as
Short Bowel Syndrome (SBS).
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
The present invention relates to use of inhibitors of the potassium channel Kv1.3 in therapeutic methods, in particular wherein the methods comprise administering the inhibitor to a subject at particular intervals.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention features methods for treating obesity and promoting weight loss by administering to a subject a combination of a GLP-1 agonist and a GIP agonist.
The present invention relates to glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), and their medical uses for the treatment of short bowel syndrome (SBS), and in particular to the treatments using glepaglutide that result in an early or significant reduction in the parenteral support (PS) required by patients undergoing GLP-2 therapy, even allowing patients to be weaned off the need for PS. In combination with a subpopulation of patients becoming SBS non-PS, the patients further reported an improvement in their Quality-of-Life (QoL).
The present invention relates to therapeutic methods using acylated compounds having dual agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 5 (glucagon-like peptide 2) receptors and a peptide hormone. In particular, the invention relates to the administration of the dual GLP-1/GLP-2 agonist peptide, and amylin for the regulation of body weight and prophylaxis or treatment of obesity and related conditions.
The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.
Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. Solid compositions comprising acetate salts of glucagon-like peptide 2 (GLP-2) analogues useful for making the liquid formulations are also described. The development of these liquid formulations is based on the finding that acetate present in the formulation that originates from the GLP-2 analogues has an effect on the viscosity of the formulation, that during long term storage at 2-8° C. of GLP-2 analogues, the concentration dependence for covalent oligomer formation is inversely dependent on increasing concentration of the GLP-2 analogue, and that GLP-2 analogues used in the formulations are not compatible with phosphate buffer commonly used in the prior art to reconstituted powdered or lyophilized GLP-2 compositions.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for treatment and prevention of stomach- and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS) Devices for introducing pharmaceutical preparations, namely, infusion and injection devices for administering drugs for treatment and prevention of stomach- and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS) Medical and pharmaceutical services, namely, medical treatment of stomach- and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS) and pharmaceutical consultation for the prevention of stomach- and bowel-related disorders and gastrointestional diseases and disorders in humans, namely, Short Bowel Syndrome (SBS); providing medical and pharmaceutical advice, in the fields of treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS)
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for treatment and prevention of stomach- and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS) Devices for introducing pharmaceutical preparations, namely, infusion and injection devices for administering drugs for treatment and prevention of stomach- and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS) Medical and pharmaceutical services, namely, medical treatment of stomach- and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS) and pharmaceutical consultation for the prevention of stomach- and bowel-related disorders and gastrointestional diseases and disorders in humans, namely, Short Bowel Syndrome (SBS); providing medical and pharmaceutical advice, in the fields of treatment and prevention of stomach and bowel-related disorders and gastrointestinal diseases and disorders in humans, namely, Short Bowel Syndrome (SBS)
43.
PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid formulations of amylin analogues.
The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid formulations of amylin analogues.
infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of congenital hyperinsulinism (CHI); medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of hypoglycemia; structural parts and fittings for infusion and injection devices for administering drugs; structural parts and fittings for infusion pumps
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
51.
PHARMACEUTICAL PARENTERAL COMPOSITION OF DUAL GLP1/2 AGONIST
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.
The present invention relates to processes for obtaining glucagon-like-peptide-2 (GLP-2) analogues, such as glepaglutide. In particular, the processes described herein use a multi-step purification method of GLP-2 analogues synthesized by solid phase peptide synthesis (SPPS).
Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are ?4?7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
54.
PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES
The present invention relates to processes for obtaining glucagon-like-peptide-2 (GLP-2) analogues, such as glepaglutide. In particular, the processes described herein use a multi-step purification method of GLP-2 analogues synthesized by solid phase peptide synthesis (SPPS).
Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
Compounds of formula (1):
and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease, such as Crohn's disease, psoriasis, and ulcerative colitis. The compounds have good physical and chemical stability in the gastrointestinal tract.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment or prevention of
gastrointestinal diseases and disorders in humans, such as
short bowel syndrome. Medical and pharmaceutical information services, namely,
medical and pharmaceutical information services relating to
the prevention or treatment of gastrointestinal diseases and
disorders in humans, such as short bowel syndrome; medical
and pharmaceutical advice, namely, providing medical and
pharmaceutical advice relating to the prevention or
treatment of gastrointestinal diseases and disorders in
humans, such as short bowel syndrome.
The present invention relates to compounds that are peptide inhibitors of interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease, such as Crohn's disease, psoriasis, and ulcerative colitis. The compounds have good physical and chemical stability in the gastrointestinal tract.
The present invention relates to an agonist combination comprising a GLP-1 agonist and a GLP-2 agonist, for use in the treatment of a patient who has undergone surgical resection of the bowel.
Processes for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, and in particular to processes for producing formulations that comprise ZP1848 (glepaglutide) or ZP1846 (elsiglutide) based on one- pot formulation.
Processes for producing a stable liquid pharmaceutical formulation comprising a glucagon-like peptide 2 (GLP-2) analogue, and in particular to processes for producing formulations that comprise ZP1848 (glepaglutide) or ZP1846 (elsiglutide) based on one- pot formulation.
The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.
The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment or prevention of gastrointestinal diseases and disorders in humans, such as short bowel syndrome. (1) Medical and pharmaceutical information services, namely, medical and pharmaceutical information services relating to the prevention or treatment of gastrointestinal diseases and disorders in humans, such as short bowel syndrome; medical and pharmaceutical advice, namely, providing medical and pharmaceutical advice relating to the prevention or treatment of gastrointestinal diseases and disorders in humans, such as short bowel syndrome.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of human patients suffering from congenital hyperinsulinism and/or hypoglycemia; Medical preparations for the treatment of human patients suffering from congenital hyperinsulinism and/or hypoglycemia Infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of congenital hyperinsulinism; medical apparatus, namely, infusion and injection devices for administering drugs for the treatment of hypoglycemia; Infusion and injection devices for administering drugs, and parts and fitting therefore, sold as a unit; Infusion pumps and parts and fittings for infusion pumps sold as a unit Medical services relating to treatment of human patients suffering from congenital hyperinsulinism and/or hypoglycemia
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of human patients suffering from congenital hyperinsulinism; Pharmaceutical preparations for the treatment of human patients suffering from congenital hypoglycemia; Medical preparations for the treatment of human patients suffering from congenital hyperinsulinism; Medical preparations for the treatment of human patients suffering from congenital hypoglycemia.
(2) Infusion pumps; medical devices, namely, infusion pumps for subcutaneous delivery of drugs; medical apparatus, namely, infusion pumps, injection needles and jet injection devices for administering drugs; medical apparatus, namely, infusion pumps, injection needles and jet injection devices for administering drugs for the treatment of congenital hyperinsulinism; medical apparatus, namely, infusion pumps, injection needles and jet injection devices for administering drugs for the treatment of hypoglycemia; Infusion pumps, injection needles and jet injection devices for administering drugs, and parts and fitting therefore, sold as a unit; Infusion pumps and parts and fittings for infusion pumps sold as a unit. (1) Medical services relating to treatment of human patients suffering from congenital hyperinsulinism; Medical services relating to treatment of human patients suffering from congenital hypoglycemia.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a composition comprising a GLP-1/GLP-2 dual agonist for use in a method for the treatment and/or prevention of diarrhea, loose stools, urgency, incontinence, high fecal output and/or high stomal output in a patient having undergone surgical resection of the bowel.
Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. Solid compositions comprising acetate salts of glucagon-like peptide 2 (GLP-2) analogues useful for making the liquid formulations are also described. The development of these liquid formulations is based on the finding that acetate present in the formulation that originates from the GLP-2 analogues has an effect on the viscosity of the formulation, that during long term storage at 2-8° C. of GLP-2 analogues, the concentration dependence for covalent oligomer formation is inversely dependent on increasing concentration of the GLP-2 analogue, and that GLP-2 analogues used in the formulations are not compatible with phosphate buffer commonly used in the prior art to reconstituted powdered or lyophilized GLP-2 compositions.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects. In particular, the present invention relates to isotonic pharmaceutical compositions for parenteral administration.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
76.
PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.
The present invention relates to dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues, and in particular to ZP1848 (glepaglutide), in patients with renal insufficiency. Unlike other GLP-2 analogues, such as teduglutide, it has been found that ZP1848 is cleared normally in patients with renal impairment. As a result, there is no need to adjust the dosage of ZP1848 depending on a patient's renal function.
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Liquid formulations of GLP-2 analogues are described that make it possible to include a preservative while allowing the formulation to be stabilised for long term storage as liquids and/or as multi-dose liquid formulations. The development of these formulations is base on the finding that that reducing the pH of the formulation to below 7.0, e.g. to a pH between about pH 5.0 and about 6.8, was able to offset the effect that the addition of a preservative such as meta-cresol has on the physical stability of the formulation. Additionally, the addition of an excipient such as propylene glycol was shown to be able to offset the effect that the addition of a preservative, such as meta-cresol, has on the physical stability of the formulation. This opens up the possibility of being able to deliver the GLP-2 analogues as multi-dose formulations, for example allowing the use of the formulations in a drug delivery device.
Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described. The compounds are α4β7 antagonists and are useful in the prevention or treatment of inflammatory conditions and/or autoimmune diseases, especially inflammatory bowel disease.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.
The present invention relates to an agonist combination comprising a GLP-1 agonist and a GLP-2 agonist, for use in the treatment of a patient who has undergone surgical resection of the bowel.
The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.
The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.
The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
printed publications, namely, brochures and newsletters in the fields of pharmaceuticals, financial support, prescription reimbursements and fulfillment and patient care providing information and support to patients and medical professionals in the fields of pharmaceuticals, namely, pharmaceutical prescription order fulfillment services, business administration of pharmacy reimbursement programs and services, and online information and telephone information services regarding the aforesaid services via an online website, call centers and SMS providing information and support to patients and medical professionals in the fields of pharmaceuticals, namely, insurance administration of prescription drug benefit plans, financial administration of pharmacy reimbursement programs and services, providing financial support to disadvantaged patients for the purpose of facilitating good health, and online information and telephone information services regarding the aforesaid services via an online website, call centers and SMS providing online email newsletters to patients and medical professionals in the fields of pharmaceuticals, financial support, prescription reimbursements and fulfillment and patient care providing online medical and scientific research information to patients and medical professionals in the fields of pharmaceuticals providing online medical information in the fields of pharmaceuticals and patient care via a website and providing online medical advice in the fields of pharmaceuticals and patient care
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
16 - Paper, cardboard and goods made from these materials
35 - Advertising and business services
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
printed publications, namely, brochures and newsletters in the fields of pharmaceuticals, financial support, prescription reimbursements and fulfillment and patient care providing information and support to patients and medical professionals in the fields of pharmaceuticals, namely, pharmaceutical prescription order fulfillment services, business administration of pharmacy reimbursement programs and services, and online information and telephone information services regarding the aforesaid services via an online website, call centers and SMS providing information and support to patients and medical professionals in the fields of pharmaceuticals, namely, insurance administration of prescription drug benefit plans, financial administration of pharmacy reimbursement programs and services, providing financial support to disadvantaged patients for the purpose of facilitating good health, and online information and telephone information services regarding the aforesaid services via an online website, call centers and SMS providing online email newsletters to patients and medical professionals in the fields of pharmaceuticals, financial support, prescription reimbursements and fulfillment and patient care providing online medical and scientific research information to patients and medical professionals in the fields of pharmaceuticals providing online medical information in the fields of pharmaceuticals and patient care via a website and providing online medical advice in the fields of pharmaceuticals and patient care
